Overview
- Features a comprehensive and detailed discussion of the biology of heparanase and heparanase-2 and its role and function in aggressive cancer phenotypes
- The book's 8 chapters are written by internationally recognized leaders in the field of heparanase biology
- Heparanase holds an important role in the development of cancer, inflammation and other diseases, which makes the book essential for both researchers and clinicians
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1221)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (37 chapters)
-
Front Matter
-
Crystal Structure, Substrate Specificity and Gene Regulation
-
Front Matter
-
-
Tumor Biology
-
Front Matter
-
-
Immune Cells
-
Front Matter
-
Keywords
About this book
Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications.
Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.
Editors and Affiliations
About the editors
Ralph Sanderson is the UAB Endowed Professor of Cancer Pathobiology and Director, Division of Molecular and Cellular Pathology, Department of Pathology, UAB O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham. Sanderson earned a B.S. from the University of Alabama, and a Ph.D. at the University of Alabama at Birmingham. His research focuses on determining how tumor-host cell interactions mediated by heparan sulfate and the enzyme heparanase regulate the tumor microenvironment and promote tumor progression, and to use that knowledge to design new cancer therapies.
Neta Ilan is a Senior Researcher at the Rappaport Faculty of Medicine and the Technion Integrated Cancer Center (TICC), Haifa, Israel. Neta earned a bachelor’s degree in Agricultural Sciences and a Master’s degree in Biotechnology from the Hebrew University of Jerusalem. Neta completed his education at the Hebrew University, with a doctorate in Animal Sciences, working on manipulation of the mammary gland of transgenic animals. He did his postdoctoral training at Yale University, focusing on tumor angiogenesis. His current research focuses on the mode of action and role of heparanase in cancer initiation, growth, and metastasis in order to address problems in the prevention, management, and treatment of cancer.
Bibliographic Information
Book Title: Heparanase
Book Subtitle: From Basic Research to Clinical Applications
Editors: Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-030-34521-1
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020
Hardcover ISBN: 978-3-030-34520-4Published: 10 April 2020
Softcover ISBN: 978-3-030-34523-5Published: 10 April 2021
eBook ISBN: 978-3-030-34521-1Published: 09 April 2020
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: XVIII, 885
Number of Illustrations: 61 b/w illustrations, 107 illustrations in colour
Topics: Cancer Research, Oncology, Molecular Medicine